E
Evommune, Inc.
EVMNCIK 0002044725NYSENon-AcceleratedSmaller ReportingEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
$13.00M
Net Income
$-68.87M
Total Assets
$224.95M
Equity
$205.57M
Shares Out
36.02M
Op. Cash Flow
$-76.44M
Business
Evommune, Inc. is a publicly listed company in Pharmaceutical Preparations, incorporated in Delaware. Common stock trades on NYSE under the ticker EVMN.
Auto-generated from company profile
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| License revenue | 13 | 7 | |
| Total revenue | 13 | 7 | |
| Research and development | 74 | 64 | |
| General and administrative | 20 | 13 | |
| Total operating expenses | 94 | 77 | |
| Loss from operations | −81 | −70 | |
| Change in fair value of convertible preferred stock forward | 9 | — | |
| Interest income | 3 | 3 | |
| Other expense, net | −50,000 | −37,000 | |
| Total other income, net | 12 | 3 | |
| Net loss | −69 | −67 | |
| Deemed dividend | — | 2 | |
| Net loss attributable to common stockholders | −69 | −68 | |
| Basic net loss per share of common stock | −11.22 | −45.29 | |
| Diluted net loss per share of common stock | −11.22 | −45.29 | |
| Weighted average basic shares of common stock outstanding | 6 | 2 | |
| Weighted average diluted shares of common stock outstanding | 6 | 2 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 44 | 16 | — | |
| Short-term investments | 105 | 56 | — | |
| Prepaid expenses and other current assets | 4 | 2 | — | |
| Total current assets | 153 | 74 | — | |
| Operating lease right-of-use assets, net | 1 | 472,000 | — | |
| Property and equipment, net | 994,000 | 1 | — | |
| Long-term investments | 67 | — | — | |
| Restricted cash | 1 | 208,000 | — | |
| Other non-current assets | 101,000 | 61,000 | — | |
| Total assets | 225 | 76 | — | |
| Accounts payable | 8 | 8 | — | |
| Accrued liabilities | 10 | 7 | — | |
| Operating lease liability, current portion | 242,000 | 487,000 | — | |
| Convertible preferred stock forward | — | 9 | — | |
| Deferred revenue | — | 3 | — | |
| Other current liabilities | 364,000 | 573,000 | — | |
| Total current liabilities | 18 | 28 | — | |
| Operating lease liability, non-current portion | 1 | — | — | |
| Financing lease liability | 181,000 | 535,000 | — | |
| Total liabilities | 19 | 29 | — | |
| Commitments and contingencies (Note 6) | — | — | — | |
| Convertible preferred stock: $0.0001 par value -10,000,000 and 157,657,729 shares authorized at December 31, 2025 and December 31, 2024, and 0 and 116,716,142 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively, (liquidation preference $0 and $210,328 at December 31, 2025 and December 31, 2024, respectively) | 0 | 192 | — | |
| Common stock, par value $0.0001 - 500,000,000 and 223,593,879 shares authorized at December 31, 2025 and December 31, 2024, respectively; 31,524,093 and 1,551,420 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 3,000 | 0 | — | |
| Additional paid-in capital | 427 | 8 | — | |
| Accumulated deficit | −221 | −152 | — | |
| Total stockholders' equity (deficit) | 206 | −144 | −78 | |
| Total liabilities, convertible preferred stock, and stockholders' equity (deficit) | 225 | 76 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Net loss | −69 | −67 | |
| Stock-based compensation expense | 6 | 2 | |
| Accretion of discount on investments | −2 | −2 | |
| Depreciation and amortization | 1 | 1 | |
| Prepaid expenses and other assets | −2 | −1 | |
| Accounts payable | −837,000 | 7 | |
| Accrued liabilities | 3 | 3 | |
| Operating lease liabilities | −730,000 | −769,000 | |
| Deferred revenue | −3 | — | |
| Net cash used in operating activities | −76 | −58 | |
| Purchases of investments | −199 | −90 | |
| Maturities of investments | 84 | 86 | |
| Purchase of property and equipment | −235,000 | −88,000 | |
| Net cash used in investing activities | −115 | −4 | |
| Proceeds from the sale of common stock in initial public offering, net of offering costs paid | 157 | — | |
| Proceeds from issuance of convertible preferred stock, net of issuance costs | 65 | 50 | |
| Proceeds from exercise of stock options | 6,000 | 13,000 | |
| Principal payments of finance lease liability | −400,000 | −200,000 | |
| Principal payments of financing obligation | −200,000 | −200,000 | |
| Taxes paid related to net share settlement of equity awards | −1 | — | |
| Net cash provided by financing activities | 221 | 49 | |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 29 | −13 | |
| Cash paid for interest | 7,000 | 34,000 | |
| Issuance of common stock upon conversion of convertible preferred stock | 257 | — | |
| Unpaid fixed asset purchases | 35,000 | — | |
| Vesting of early exercised stock options | 40,000 | 50,000 | |
| Assets acquired under finance leases | 10,000 | 1 | |
| Deferred offering costs in accounts payable | 294,000 | — | |
| Operating lease liabilities arising from obtaining right-of-use assets | 2 | — | |
| Deemed dividend from trigger of anti-dilution provision feature | — | 2 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro